Benitec Biopharma (ASX:BLT) 3-Year FCF Growth Rate : -20.00% (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Benitec Biopharma 3-Year FCF Growth Rate?

Benitec Biopharma's Free Cash Flow per Share for the three months ended in Mar. 2024 was A$-0.03.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -20.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 11 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Benitec Biopharma was 50.70% per year. The lowest was -20.00% per year. And the median was 26.65% per year.

Competitive Comparison of Benitec Biopharma's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Benitec Biopharma's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benitec Biopharma's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's 3-Year FCF Growth Rate falls into.

Benitec Biopharma 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Benitec Biopharma (ASX:BLT) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Benitec Biopharma 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Benitec Biopharma (ASX:BLT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (ASX:BLT) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

BNTC:USA

Address

3940 Trust Way, Hayward, CA, USA, 94545

Website

https://www.benitec.com

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.